GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OncoSil Medical Ltd (ASX:OSL) » Definitions » Valuation Rank

OncoSil Medical (ASX:OSL) Valuation Rank


View and export this data going back to 2005. Start your Free Trial

What is OncoSil Medical Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

OncoSil Medical Valuation Rank Related Terms

Thank you for viewing the detailed overview of OncoSil Medical's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSil Medical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OncoSil Medical Ltd (ASX:OSL) » Definitions » Valuation Rank
Comparable Companies
ASX:UBI ASX:LDX ASX:EYE ASX:HMD ASX:NTI ASX:CDX ASX:CBL ASX:AT1 ASX:ADRDA ASX:UCM ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
N/A
Address
7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113
Website
https://www.oncosil.com
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.